Skip to main content
logo
Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
43.27
-0.38 (-0.87%)
Oct 1, 2026, 3:11 PM EDT - Market open

Boston Scientific Revenue by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Cardiology
13.25B12.27B11.19B10.01B9.50B8.90B8.35B7.80BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Cardiology Growth
39.39%37.81%34.14%28.40%29.86%27.65%24.40%20.24%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Endoscopy
3.04B2.98B2.92B2.85B2.78B2.72B2.69B2.64BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Endoscopy Growth
9.25%9.64%8.56%7.80%7.18%6.67%8.22%9.68%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Urology
2.73B2.72B2.71B2.62B2.47B2.32B2.20B2.10BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Urology Growth
10.48%17.33%23.14%24.99%20.65%15.54%12.02%9.56%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Neuromodulation
1.28B1.25B1.20B1.17B1.14B1.12B1.11B1.08BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Neuromodulation Growth
12.53%11.25%8.51%8.47%10.14%12.22%13.22%12.45%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Peripheral Interventions
702.00M1.40B2.06B2.70B2.60B2.49B2.41B2.30BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Peripheral Interventions Growth
-73.01%-43.84%-14.69%17.54%16.43%14.41%14.27%11.99%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Revenue by Geography

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
13.39B13.19B12.86B12.37B11.67B10.91B10.21B9.53BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
United States Growth
14.74%20.86%25.99%29.81%29.15%25.71%21.19%16.25%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
EMEA
3.59B3.54B3.45B3.35B3.33B3.27B3.23B3.15BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
EMEA Growth
7.94%8.13%6.91%6.36%9.26%11.03%13.06%13.90%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
APAC
3.27B3.18B3.08B2.98B2.86B2.74B2.69B2.62BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
APAC Growth
14.38%16.17%14.71%13.76%12.38%9.56%11.83%12.75%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
LACA
745.00M708.00M678.00M654.00M638.00M631.00M625.00M618.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
LACA Growth
16.77%12.20%8.48%5.83%5.45%8.23%11.61%15.73%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Operating Expense Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Selling, General, and Administrative
7.16B7.07B6.89B6.67B6.49B6.22B5.98B5.75BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Selling, General, and Administrative Growth
10.34%13.74%15.09%15.91%19.44%16.45%15.30%15.62%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Research and Development
2.15B2.13B2.05B1.94B1.84B1.69B1.62B1.52BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Research and Development Growth
17.27%25.52%26.98%27.91%25.07%17.24%14.20%9.91%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Amortization
918.00M910.00M897.00M894.00M874.00M862.00M857.00M840.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Amortization Growth
5.03%5.57%4.67%6.43%3.68%2.62%3.38%2.44%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Litigation-related Net Charges
270.00M194.00M194.00M-----UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Royalty Expense
42.00M44.00M46.00M50.00M43.00M38.00M34.00M36.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Royalty Expense Growth
-2.33%15.79%35.29%38.89%2.38%-15.56%-26.09%-23.40%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Restructuring Net Charges
19.00M94.00M101.00M89.00M105.00M23.00M16.00M31.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Restructuring Net Charges Growth
-81.90%308.70%531.25%187.10%176.32%-56.60%-77.14%-45.61%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Asset and Goodwill Impairment
-46.00M46.00M157.00M157.00M387.00M387.00M276.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Asset and Goodwill Impairment Growth
--88.11%-88.11%-43.12%-43.32%567.24%567.24%375.86%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Contingent Consideration Net Expense
-28.00M-17.00M18.00M10.00M-24.00M-17.00M-5.00M10.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade